Cargando…
A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
BACKGROUND: The Single-Point Insulin Sensitivity Estimator (SPISE) is a biomarker of insulin sensitivity estimated using BMI and triglycerides and high-density lipoprotein cholesterol. We assessed the accuracy of SPISE to screen obesity-related cardiometabolic risk in children and adolescents. METHO...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945119/ https://www.ncbi.nlm.nih.gov/pubmed/36843603 http://dx.doi.org/10.3389/fendo.2023.1078949 |
_version_ | 1784892070954008576 |
---|---|
author | Correa-Burrows, Paulina Matamoros, Mariela de Toro, Valeria Zepeda, Diego Arriaza, Marta Burrows, Raquel |
author_facet | Correa-Burrows, Paulina Matamoros, Mariela de Toro, Valeria Zepeda, Diego Arriaza, Marta Burrows, Raquel |
author_sort | Correa-Burrows, Paulina |
collection | PubMed |
description | BACKGROUND: The Single-Point Insulin Sensitivity Estimator (SPISE) is a biomarker of insulin sensitivity estimated using BMI and triglycerides and high-density lipoprotein cholesterol. We assessed the accuracy of SPISE to screen obesity-related cardiometabolic risk in children and adolescents. METHOD: Cross-sectional validation study for a screening test in a sample of n=725 children and adolescents from an obesity clinic. Weight, height, waist circumference, blood arterial pressure, lipid profile, glucose, insulin and Tanner stage were measured. BMI, BMI for-age-and sex (BAZ), and HOMA-IR were estimated. HOMA-IR values ≥2.1 and ≥3.3 were considered IR in Tanner I-II, ≥3.3 for Tanner III-IV and ≥2.6 for Tanner V, respectively. Metabolic Syndrome (MetS) was diagnosed with the Cook phenotype. SPISE was estimated according to the following algorithm: [600* HDL^0.185/(TG^0.2* BMI^1.338)]. The optimal SPISE cut points for IR and MetS prediction were determined by ROC curve analysis. RESULTS: In prepubertal obese patients (9.2 ± 2.1y; 18.4% males), the prevalence of IR and MetS was 28.2% y 46.9%, respectively; 58% had severe obesity (BAZ ≥4 SD). In pubertal obese patients (12.6 ± 1.8y; 57% males), the prevalence of IR and MetS was 34.1% and 55.3%, respectively; 34% had severe obesity. In prepubertal children, a SPISE of 6.3 showed the highest sensitivity (73.2%) and specificity (80%) to screen individuals with IR (AUC: 0.80; LR +: 3.3). Likewise, a SPISE of 5.7 got the highest sensitivity (82.6%) and specificity (86.1%) to screen patients with MetS (AUC: 0.87; LR +: 5.4). In pubertal patients, a SPISE of 5.4 showed the highest sensitivity and specificity to screen children and adolescents with both IR (Sn: 76.1%; Sp: 77.5%; AUC: 0.8; LR +: 3.1) and MetS (Sn: 90.4%; Sp: 76.1%; AUC: 0.90; LR +: 3.5). CONCLUSION: In children and adolescents with obesity, SPISE has good or very good performance in predicting IR and MetS. SPISE may be considered a relatively simple and low-cost diagnosis tool that can be helpful to identify patients with greater biological risk. In adolescents with obesity, the same cut point allows identification of those at higher risk of both IR and MetS. |
format | Online Article Text |
id | pubmed-9945119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99451192023-02-23 A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity Correa-Burrows, Paulina Matamoros, Mariela de Toro, Valeria Zepeda, Diego Arriaza, Marta Burrows, Raquel Front Endocrinol (Lausanne) Endocrinology BACKGROUND: The Single-Point Insulin Sensitivity Estimator (SPISE) is a biomarker of insulin sensitivity estimated using BMI and triglycerides and high-density lipoprotein cholesterol. We assessed the accuracy of SPISE to screen obesity-related cardiometabolic risk in children and adolescents. METHOD: Cross-sectional validation study for a screening test in a sample of n=725 children and adolescents from an obesity clinic. Weight, height, waist circumference, blood arterial pressure, lipid profile, glucose, insulin and Tanner stage were measured. BMI, BMI for-age-and sex (BAZ), and HOMA-IR were estimated. HOMA-IR values ≥2.1 and ≥3.3 were considered IR in Tanner I-II, ≥3.3 for Tanner III-IV and ≥2.6 for Tanner V, respectively. Metabolic Syndrome (MetS) was diagnosed with the Cook phenotype. SPISE was estimated according to the following algorithm: [600* HDL^0.185/(TG^0.2* BMI^1.338)]. The optimal SPISE cut points for IR and MetS prediction were determined by ROC curve analysis. RESULTS: In prepubertal obese patients (9.2 ± 2.1y; 18.4% males), the prevalence of IR and MetS was 28.2% y 46.9%, respectively; 58% had severe obesity (BAZ ≥4 SD). In pubertal obese patients (12.6 ± 1.8y; 57% males), the prevalence of IR and MetS was 34.1% and 55.3%, respectively; 34% had severe obesity. In prepubertal children, a SPISE of 6.3 showed the highest sensitivity (73.2%) and specificity (80%) to screen individuals with IR (AUC: 0.80; LR +: 3.3). Likewise, a SPISE of 5.7 got the highest sensitivity (82.6%) and specificity (86.1%) to screen patients with MetS (AUC: 0.87; LR +: 5.4). In pubertal patients, a SPISE of 5.4 showed the highest sensitivity and specificity to screen children and adolescents with both IR (Sn: 76.1%; Sp: 77.5%; AUC: 0.8; LR +: 3.1) and MetS (Sn: 90.4%; Sp: 76.1%; AUC: 0.90; LR +: 3.5). CONCLUSION: In children and adolescents with obesity, SPISE has good or very good performance in predicting IR and MetS. SPISE may be considered a relatively simple and low-cost diagnosis tool that can be helpful to identify patients with greater biological risk. In adolescents with obesity, the same cut point allows identification of those at higher risk of both IR and MetS. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9945119/ /pubmed/36843603 http://dx.doi.org/10.3389/fendo.2023.1078949 Text en Copyright © 2023 Correa-Burrows, Matamoros, de Toro, Zepeda, Arriaza and Burrows https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Correa-Burrows, Paulina Matamoros, Mariela de Toro, Valeria Zepeda, Diego Arriaza, Marta Burrows, Raquel A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity |
title | A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity |
title_full | A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity |
title_fullStr | A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity |
title_full_unstemmed | A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity |
title_short | A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity |
title_sort | single-point insulin sensitivity estimator (spise) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945119/ https://www.ncbi.nlm.nih.gov/pubmed/36843603 http://dx.doi.org/10.3389/fendo.2023.1078949 |
work_keys_str_mv | AT correaburrowspaulina asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT matamorosmariela asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT detorovaleria asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT zepedadiego asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT arriazamarta asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT burrowsraquel asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT correaburrowspaulina singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT matamorosmariela singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT detorovaleria singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT zepedadiego singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT arriazamarta singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity AT burrowsraquel singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity |